Expert opinion on investigational drugs · 2013
Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Antoniu Sabina, Azoicai Doina
Аннотация
INTRODUCTION: In non-cystic fibrosis (CF) bronchiectasis, the chronic airways infection is a risk factor for frequent infectious exacerbations and for an overall poor disease prognosis. Its therapy with inhaled antibiotics might be useful alike in the case of the CF-related disease.
AREAS COVERED: Analysis and discussion of the results of a Phase II study evaluating the efficacy and safety of the inhaled ciprofloxacin-dry powder (C-DPI) formulation in patients with non-CF bronchiectasis.
EXPERT OPINION: On short-term basis C-DPI is able to reduce the sputum bacterial load in such patients but long-term studies are also needed to better characterize the clinical efficacy of this compound.
AREAS COVERED: Analysis and discussion of the results of a Phase II study evaluating the efficacy and safety of the inhaled ciprofloxacin-dry powder (C-DPI) formulation in patients with non-CF bronchiectasis.
EXPERT OPINION: On short-term basis C-DPI is able to reduce the sputum bacterial load in such patients but long-term studies are also needed to better characterize the clinical efficacy of this compound.